Fosphomycin: A ray of hope against multidrug resistant uropathogens
- Author:
Sarita Mohapatra
1
;
Biswajeet Sahoo
1
;
Shivani Bhatia
1
;
Seema Sood
1
;
Bimal Ku Das
1
;
Arti Kapil
1
Author Information
- Publication Type:Journal Article
- Keywords: Urinary tract infection; ESBL producer; carbapenem resistance; Fosphomycin; Nitrofurantoin
- From:Malaysian Journal of Microbiology 2019;15(6):488-491
- CountryMalaysia
- Language:English
-
Abstract:
Aims:Urinary Tract Infection (UTI) is one of the common infections in clinical practice. Increasing incidence of Multi Drug Resistant (MDR) uropathogens limited the therapeutic options; thereby prompted the interest in old drugs like Fosphomycin. The current study was undertaken for the comparative evaluation of vitro activity of Fosphomycin and Nitrofurantoin against ESBL producing and carbapenem resistant uropathogens. We also tried to compare the coexistence of resistance of both the drugs with another commonly used oral drug for UTI, i.e. Flouroquinolone.
Methodology and results:A total 101 MDR uropathogens were tested for ESBL production, carbapenem resistance, Fosphomycin susceptibility and Nitrofurantoin susceptibility as per the CLSI guidelines. Fosphomycin susceptibility testing was carried out by disc diffusion test. Klebsiella pneumoniae was the commonest MDR uropathogen followed by Pseudomonas aeruginosa and Escherichia coli. Susceptibility to Fosphomycin among the ESBL producer and carbapenem resistant uropathogen was found uniformly higher (91.8%, 90.1%) in comparison to Nitrofurantion (27.5%, 21.3%). Coexistence of resistance to Fosphomycin was much less than Nitrofurantoin in presence of resistance to Flouroquinolone.
Conclusion, significance and impact of study:Fosphomycin showed excellent in vitro susceptibility against both ESBL producing and carbapenem resistant MDR uropathogens. Fosphomycin has excellent in vitro action of Fosphomycin against ESBL producing and carbapenem resistance uropathogen in comparison to Nitrofurantoin, hence will be useful for the treatment of drug resistsant uropathogens. - Full text:20.2019my0568.pdf
